Fig. 1

P5C inhibits T cells proliferation and SHP1 participates in energy and carbonhydrate metabolism. A CFSE-labeled human primary CD3⁺ T cells were pretreated with PCM or P5C for 3 days with anti-CD3/CD28 Ab. T-cell proliferation was evaluated by FACS analysis. The right side of graph is the representative result of CD3⁺ T cells proliferation. B Jurkat cells were treated with PCM or P5C for 72 h. Shown is the percentage of cell proliferation by CCK-8 assay. One representative experiment out of three performed. C Western bolt showing the protein expression of SHP1 in Jurkat cells after treatment with PCM or P5C. An antibody to GAPDH was used as a loading control. D SHP1 was captured from Jurkat cells after treated with P5C, and all the proteins bound with SHP1 were checked by LC/MS-MS. Through GO analysis, differential GO term in biological process (BP), cellular component (CC) and Molecular Function (MF) are shown. E All the proteins bound with SHP1 were summarized and shown in KEGG pathway. F The proteins bound with SHP1 and involved in glucose metabolism are shown. PKM2 and LDHB are marked by red rectangle. Error bars are SEM of biological replicates and ^***p < 0.01